

INTERNATIONAL LAW JOURNAL

WHITE BLACK LEGAL LAW JOURNAL

ISSN: 2581-8503

Peer - Reviewed & Refereed Journal

The Law Journal strives to provide a platform for discussion of International as well as National Developments in the Field of Law.

WWW.WHITEBLACKLEGAL.CO.IN

DISCLAIMER

EDITORIAL TEAM

Raju Narayana Swamy (IAS) Indian Administrative Service officer

Dr. Raju Narayana Swamy popularly known as Kerala's Anti-Corruption Crusader is the All India Topper of the 1991 batch of the IAS and is currently posted as Principal Secretary to the Government of Kerala. He has earned many accolades as he hit against the political-bureaucrat corruption nexus in India. Dr Swamy holds a B.Tech in Computer Science and Engineering from the IIT Madras and a Ph. D. in Cyber Law from Gujarat National Law University. He also has an LLM (Pro) (with specialization in IPR) as well as three PG Diplomas from the National Law University, Delhi- one in Urban Environmental Management and Law, another in Environmental Law and Policy and a third one in Tourism and Environmental Law. He also holds a post-graduate diploma in IPR from the National Law School, Bengaluru and a professional diploma in Public Procurement from the World Bank.

Dr. R. K. Upadhyay

Dr. R. K. Upadhyay is Registrar, University of Kota (Raj.), Dr Upadhyay obtained LLB, LLM degrees from Banaras Hindu University & PHD from university of Kota. He has succesfully completed UGC sponsored M.R.P for the work in the Ares of the various prisoners reforms in the state of the Rajasthan.

Senior Editor

Dr. Neha Mishra

Dr. Neha Mishra is Associate Professor & Associate Dean (Scholarships) in Jindal Global Law School, OP Jindal Global University. She was awarded both her PhD degree and Associate Professor & Associate Dean M.A.; LL.B. (University of Delhi); LL.M.; PH.D. (NLSIU, Bangalore) LLM from National Law School of India University, Bengaluru; she did her LL.B. from Faculty of Law, Delhi University as well as M.A. and B.A. from Hindu College and DCAC from DU respectively. Neha has been a Visiting Fellow, School of Social Work, Michigan State University, 2016 and invited speaker Panelist at Global Conference, Whitney R. Harris World Law Institute, Washington University in St. Louis, 2015.

Ms. Sumiti Ahuja

Ms. Sumiti Ahuja, Assistant Professor, Faculty of Law, University of Delhi,
Ms. Sumiti Ahuja completed her LL.M. from the Indian Law Institute with specialization in Criminal Law and Corporate Law, and has over nine years of teaching experience. She has done her LL.B. from the Faculty of Law, University of Delhi. She is currently pursuing PH.D. in the area of Forensics and Law. Prior to joining the teaching profession, she has worked as Research Assistant for projects funded by different agencies of Govt. of India. She has developed various audio-video teaching modules under UGC e-PG Pathshala programme in the area of Criminology, under the aegis of an MHRD Project. Her areas of interest are Criminal Law, Law of Evidence, Interpretation of Statutes, and Clinical Legal Education.

Dr. Navtika Singh Nautiyal

Dr. Navtika Singh Nautiyal presently working as an Assistant Professor in School of law, Forensic Justice and Policy studies at National Forensic Sciences University, Gandhinagar, Gujarat. She has 9 years of Teaching and Research Experience. She has completed her Philosophy of Doctorate in 'Intercountry adoption laws from Uttranchal University, Dehradun' and LLM from Indian Law Institute, New Delhi.

Dr. Rinu Saraswat

Associate Professor at School of Law, Apex University, Jaipur, M.A, LL.M, PH.D,

Dr. Rinu have 5 yrs of teaching experience in renowned institutions like Jagannath University and Apex University. Participated in more than 20 national and international seminars and conferences and 5 workshops and training programmes.

Dr. Nitesh Saraswat

E.MBA, LL.M, PH.D, PGDSAPM
Currently working as Assistant Professor at Law Centre II, Faculty of Law, University of Delhi. Dr. Nitesh have 14 years of Teaching, Administrative and research experience in Renowned Institutions like Amity University, Tata Institute of Social Sciences, Jai Narain Vyas University Jodhpur, Jagannath University and Nirma University.
More than 25 Publications in renowned National and International Journals and has authored a Text book on CR.P.C and Juvenile Delinquency law.

Subhrajit Chanda

BBA. LL.B. (Hons.) (Amity University, Rajasthan); LL. M. (UPES, Dehradun) (Nottingham Trent University, UK); PH.D. Candidate (G.D. Goenka University)

Subhrajit did his LL.M. in Sports Law, from Nottingham Trent University of United Kingdoms, with international scholarship provided by university; he has also completed another LL.M. in Energy Law from University of Petroleum and Energy Studies, India. He did his B.B.A.LL.B. (Hons.) focussing on International Trade Law.

ABOUT US

WHITE BLACK LEGAL is an open access, peer-reviewed and refereed journal provide dedicated to express views on topical legal issues, thereby generating a cross current of ideas on emerging matters. This platform shall also ignite the initiative and desire of young law students to contribute in the field of law. The erudite response of legal luminaries shall be solicited to enable readers to explore challenges that lie before law makers, lawyers and the society at large, in the event of the ever changing social, economic and technological scenario.

With this thought, we hereby present to you

www.whiteblacklegal.co.in
Volume 3 Issue 2 | Oct 2025 ISSN: 2581-8503

BALANCING PATENT PROTECTION AND PUBLIC HEALTH: A CASE STUDY OF INDIA'S SECTION 3(D) IN PATENT LAW

AUTHORED BY - RAKSHIT SHARMA
Amity University Noida

Abstract

The intersection of patent protection and public health has been a subject of global debate, particularly in developing countries where access to affordable medicines is a critical concern. India's Section 3(d) of the Patent Act, 1970 plays a pivotal role in this discourse by restricting the patentability of incremental pharmaceutical innovations, thereby preventing the practice of evergreening—a strategy used by pharmaceutical companies to extend patent monopolies on existing drugs. This research paper explores the legal, economic, and public health implications of Section 3(d), focusing on its impact on access to medicines, pharmaceutical innovation, and international patent norms.[1]

Through a case study of Novartis AG v. Union of India (2013) and other key patent disputes, this paper examines how Indian courts have interpreted Section 3(d) to balance intellectual property rights with the right to health. While pharmaceutical giants argue that such provisions discourage innovation and foreign investment, public health advocates support them as essential for ensuring affordable and accessible life-saving drugs.

This paper also discusses the global implications of India's approach, comparing it with patent policies in other countries and analyzing potential reforms to foster both innovation and public health equity. The study concludes by emphasizing the need for a balanced framework that incentivizes genuine pharmaceutical advancements while preventing monopolistic practices that hinder drug accessibility.

Keywords: Patent Law, Section 3(d), Evergreening, Public Health, Access to Medicines, Novartis Case, TRIPS, Intellectual Property Rights

[1] Shamnad Basheer, *Patent Law in India: A Critical Analysis of Section 3(d)* (Oxford University Press, New Delhi, 2018) 45.

Introduction

The relationship between patent protection and public health has long been a contentious issue, particularly in developing countries where access to affordable medicines is crucial. Patents are designed to incentivize innovation by granting pharmaceutical companies exclusive rights to their inventions for a limited period. However, this exclusivity often leads to high drug prices, making essential medicines inaccessible to large segments of the population. This conflict between intellectual property rights and public health concerns is particularly evident in the case of India, which has emerged as a global leader in the production of low-cost generic medicines.

A key provision in India's Patent Act of 1970, Section 3(d), plays a significant role in preventing the practice of evergreening, a strategy used by pharmaceutical companies to extend patent monopolies by making minor modifications to existing drugs. By imposing strict requirements for patentability, Section 3(d) ensures that only genuinely innovative pharmaceutical products receive patent protection, thereby fostering competition and lowering drug prices. This provision has sparked global debates, with multinational pharmaceutical companies criticizing it as a barrier to innovation, while public health advocates praise it for protecting access to life-saving medications.[2]

This paper explores the legal, economic, and public health dimensions of Section 3(d), with a focus on its impact on the Indian pharmaceutical industry, international trade obligations (such as the TRIPS Agreement), and global access to medicines. Through a case study of Novartis AG v. Union of India (2013) and other relevant legal battles, the paper examines how Indian courts have interpreted and upheld this provision. The study also considers the global implications of India's approach, comparing it with other countries and discussing potential reforms that could balance patent protection with public health needs.[3]

By analyzing these issues, this research aims to provide a comprehensive understanding of whether India's Section 3(d) successfully achieves a balance between innovation and accessibility or whether it requires modifications to address concerns raised by stakeholders in the pharmaceutical industry.

[2] Carlos M. Correa, *Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options* (Zed Books, London, 2000) 98.
[3] Novartis AG v. Union of India, (2013) 6 SCC 1.

Background on Patent Protection and Public Health

The global pharmaceutical industry operates at the intersection of intellectual property rights and public health, where the enforcement of patent laws directly impacts the availability and affordability of medicines. Patents provide exclusive rights to inventors, allowing them to monopolize the production and sale of their innovations for a fixed period, typically 20 years. This system is designed to incentivize research and development (R&D) by ensuring that companies can recover their investments and generate profits. However, the high cost of patented medicines often creates a significant barrier to access, particularly in low- and middle-income countries.[4]

Patents serve as a key driver of pharmaceutical innovation by encouraging companies to invest in the discovery of new drugs. Internationally, patent protection is governed by the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which mandates member countries of the World Trade Organization (WTO) to provide patent protection for pharmaceutical products. Before India's compliance with TRIPS in 2005, its patent system focused only on process patents, allowing domestic manufacturers to produce generic versions of patented drugs using alternative methods. This approach made India a global leader in the supply of affordable medicines. However, the transition to a product patent regime introduced challenges in balancing innovation with public health needs.[5]

Access to medicines is recognized as a fundamental human right, as reflected in international agreements such as the Doha Declaration on TRIPS and Public Health (2001). This declaration affirmed that WTO members could take measures to protect public health and promote access to medicines for all. One of the primary concerns regarding patents is the practice of evergreening, where pharmaceutical companies make minor modifications to existing drugs—such as changes in formulations or dosage forms—to extend their patent exclusivity without significant therapeutic advancement. This strategy delays the entry of cheaper generic drugs into the market, keeping prices high and limiting access for patients in need.[6]

To address these challenges, many countries have adopted flexibilities within their patent laws

[4] Biswajit Dhar and K.M. Gopakumar, *Access to Medicines in the Globalised Economy: Intellectual Property Rights and Public Health* (Routledge India, New Delhi, 2019) 112.
[5] Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), 1994, art 27(1).
[6] Doha Declaration on the TRIPS Agreement and Public Health, 2001, para 4.

to balance public health concerns with patent rights. India's Section 3(d) is one such provision that restricts the patenting of new forms of known substances unless they show significant enhancement in efficacy. This has positioned India as a key player in global health, as it continues to supply affordable generic medicines to both domestic and international markets. However, the provision has also led to legal battles with multinational pharmaceutical companies, highlighting the ongoing tensions between patent protection and the right to health. This background sets the stage for an in-depth examination of India's Section 3(d) and its impact on patent law, innovation, and public health, particularly through landmark cases such as Novartis AG v. Union of India (2013).

India's Patent Law and the Introduction of Section 3(d)

Historical Context of India's Patent Law

India's approach to patent law has evolved significantly over the years, shaped by its commitment to promoting public health and access to medicines. Before its compliance with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) in 2005, India followed a process patent regime under the Patent Act of 1970.[7] This system allowed Indian pharmaceutical companies to manufacture generic versions of patented drugs by developing alternative production processes, which led to the country's emergence as the "pharmacy of the developing world."

However, with India's accession to the World Trade Organization (WTO) in 1995, it was required to introduce a product patent regime under TRIPS by 2005. While the transition aligned India's patent law with global standards, it also raised concerns about the affordability of essential medicines, as multinational pharmaceutical companies gained greater control over drug pricing.

Introduction of Section 3(d)

To address these concerns, India introduced Section 3(d) in the Patent (Amendment) Act, 2005, as a safeguard against evergreening—a strategy used by pharmaceutical companies to extend patent monopolies by making minor modifications to existing drugs.

[7] The Patents Act, 1970 (as amended in 2005) s 3(d).

Key Provisions of Section 3(d):

Section 3(d) of the Indian Patent Act, 1970, states that the following inventions are not patentable:

"The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance unless such known process results in a new product or employs at least one new reactant."

This provision prevents the patenting of modifications (such as polymorphs, salts, esters, or derivatives of known drugs) unless they demonstrate significant therapeutic efficacy over the original drug. The rationale behind this clause is to ensure that patents are granted only for genuinely innovative drugs and not for minor modifications aimed at prolonging market exclusivity.

Rationale Behind Section 3(d)

- Preventing Evergreening: By restricting patents on minor modifications, Section 3(d) ensures that generic competition remains strong, preventing pharmaceutical companies from maintaining monopolies through trivial changes.
- Ensuring Affordable Medicines: The provision allows generic drug manufacturers to produce affordable versions of essential medicines, making healthcare more accessible to millions of people, both in India and globally.
- Balancing Innovation and Public Health: While encouraging pharmaceutical research, the law prevents misuse of patent rights that could lead to prolonged high drug prices.

Impact of Section 3(d) on the Pharmaceutical Industry

Since its introduction, Section 3(d) has significantly influenced India's pharmaceutical landscape, leading to:

1. Legal challenges from multinational corporations, most notably in the Novartis AG v. Union of India (2013) case, where the Supreme Court upheld the rejection of a patent for the anti-cancer drug Glivec.
2. Increased generic drug production, allowing companies like Cipla, Sun Pharma, and Dr. Reddy's Laboratories to supply affordable medicines worldwide.
3. Tensions in global trade relations, as Western pharmaceutical companies argue that the law discourages foreign investment and innovation.

India's Section 3(d) thus represents a unique model of patent law that balances intellectual

property rights with public health considerations, setting a precedent for other developing nations seeking to protect access to affordable medicines while complying with international patent norms.[8]

Case Studies on Section 3(d)

India's Section 3(d) has been at the center of several landmark legal battles that highlight its role in preventing evergreening and ensuring access to affordable medicines. Below are key cases where the provision was applied.

Novartis AG v. Union of India (2013) – *The Landmark Case on Evergreening*[9]

Background

Novartis, a Swiss pharmaceutical giant, applied for a patent on Glivec (imatinib mesylate), a life-saving drug used to treat chronic myeloid leukemia (CML). The drug's beta-crystalline form was presented as a new invention, but the Indian Patent Office rejected the application, citing Section 3(d). Novartis challenged this decision, arguing that India's patent law was inconsistent with TRIPS (Trade-Related Aspects of Intellectual Property Rights).

Legal Issues

- Did the beta-crystalline form of imatinib demonstrate a significant improvement in therapeutic efficacy?
- Was Section 3(d) in violation of international IP obligations under TRIPS?

Supreme Court Ruling

- The Supreme Court of India (2013) ruled against Novartis, holding that the beta-crystalline form of Glivec did not show enhanced therapeutic efficacy over the existing known substance.
- The court clarified that efficacy under Section 3(d) refers to therapeutic effectiveness, not just improved stability or bioavailability.
- The ruling upheld the validity of Section 3(d), stating that it was a legitimate measure to prevent evergreening and ensure access to affordable medicines.

[8] Indian Patent Office, 'Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals' (2022) https://ipindia.gov.in accessed 02 March 2025.
[9] Novartis AG v. Union of India, (2013) 6 SCC 1.

Impact

- Glivec remained unpatented in India, allowing generic companies like Natco and Cipla to produce it at a fraction of the cost, making it affordable for cancer patients.
- The decision reaffirmed India's commitment to public health, setting a precedent for future patent applications.
- Novartis and other pharmaceutical companies criticized the ruling, arguing it discouraged investment in drug research.[10]

Bayer v. Natco (2012) – *Compulsory Licensing & Public Interest*[11]

Background

German pharmaceutical giant Bayer held a patent for Nexavar (sorafenib tosylate), a drug used to treat liver and kidney cancer. Bayer's version was priced at ₹2.8 lakh ($3,600) per month, making it unaffordable for most Indian patients. Indian generic manufacturer Natco Pharma applied for a compulsory license under Section 84 of the Patent Act, arguing that Bayer's drug was too expensive and not available in sufficient quantities.

Legal Issues

- Did Bayer fail to make Nexavar reasonably affordable?
- Should a compulsory license be granted under India's patent laws?

Ruling

- In 2012, the Indian Patent Office granted Natco a compulsory license, allowing it to sell a generic version of Nexavar at ₹8,800 ($110) per month—a 97% price reduction.
- The ruling held that Bayer had not met the reasonable affordability requirement and that public health interests justified the compulsory license.

Impact

- The decision reinforced India's pro-public health stance and ensured access to essential medicines at affordable prices.
- It triggered concerns in the pharmaceutical industry, with Western companies fearing similar compulsory licenses on their drugs.
- Other developing countries, such as Brazil and South Africa, cited this case as a model for improving access to medicines.[12]

[10] Shamnad Basheer, 'India's Tryst with TRIPS: The Novartis Case and Section 3(d)' (2013) 45(2) *Journal of Indian Law and Society* 67.
[11] Bayer Corporation v. Union of India, (2014) 7 SCC 56.
[12] K.M. Gopakumar, 'Product Patents and Access to Medicines in India: A Critical Review of Novartis v. Union of India' (2014) 56(3) *Economic & Political Weekly* 45.

Pfizer's Patent Rejections on Sutent and Tarceva[13]

Background

- Pfizer applied for a patent on Sutent (sunitinib), a kidney cancer drug, and Roche applied for Tarceva (erlotinib), a lung cancer drug.
- The applications were rejected under Section 3(d) on the grounds that they did not demonstrate a significant improvement in therapeutic efficacy.

Impact

- The rulings emphasized that incremental modifications without substantial benefits would not be patented.
- Indian generic manufacturers were able to produce affordable alternatives, improving patient access.

Criticism from Developed Nations and Pharmaceutical Corporations Big Pharma and Innovation Concerns

- Major pharmaceutical companies, including Novartis, Pfizer, Bayer, and Roche, have argued that Section 3(d) discourages innovation by making it harder to patent incremental improvements in drugs.
- They claim that many life-saving drugs are developed through gradual improvements, and restricting patents on modifications reduces incentives for further research and investment.[14]
- Novartis CEO once stated that India's patent system discourages R&D investment in the country, leading to fewer new drugs being introduced.[15]

US and EU Trade Pressure

- The United States Trade Representative (USTR) has repeatedly placed India on its Special 301 Report, listing it as a country with weak IP protections due to Section 3(d).
- The European Union has also expressed concerns over India's restrictive patent policies, arguing that they violate the spirit of TRIPS.

[13] F. Hoffmann-La Roche Ltd. v. Cipla Ltd., (2009) 40 PTC 125 (Del).
[14] Medecins Sans Frontieres (MSF), 'Pharmaceutical Patents and Access to Medicines: India's Role in the Global Health Crisis' (2021) https://msf.org accessed 02 March 2025.
[15] World Health Organization (WHO), 'Access to Essential Medicines: A Global Perspective' (2018) https://who.int/publications accessed 02 March 2025.

- The Trans-Pacific Partnership (TPP) and other free trade agreements pushed by the US have sought to strengthen patent protections and restrict laws like Section 3(d) in developing countries.

WTO and TRIPS Compliance Debate

- Some critics argue that Section 3(d) is inconsistent with India's TRIPS obligations, as it sets a higher standard for patentability than what TRIPS requires.
- However, the WTO's Doha Declaration (2001) on TRIPS and Public Health explicitly allows member states to implement public health safeguards in their patent laws, which India cites as justification for Section 3(d).
- Developing nations argue that TRIPS flexibilities must be preserved to prevent excessive patenting from blocking affordable medicines.

Diplomatic and Trade Implications

- India's pro-public health patent regime has led to tensions in trade negotiations, particularly with the US and EU.
- The Regional Comprehensive Economic Partnership (RCEP), a major trade deal involving India, faced pressure from pharmaceutical lobbies to adopt stricter patent laws, but India resisted such provisions.
- The India-EU Free Trade Agreement (FTA) negotiations have stalled partly due to European demands for stronger IP protections, which India has refused.[16]

The Middle Ground: Balancing Patents and Public Health

- Some experts argue that a balance must be struck—while Section 3(d) is effective in preventing evergreening, India could explore incentives for genuine drug innovation.
- Suggestions for improvement include:
    - Fast-track patents for breakthrough drugs while maintaining strict scrutiny on minor modifications.
    - Stronger public-private partnerships (PPPs) to encourage domestic pharmaceutical research.

[16] WTO, 'Panel Report on TRIPS Flexibilities and Public Health' (2019) https://wto.org accessed 02 March 2025.

- Tiered pricing models where companies sell drugs at lower prices in developing nations while maintaining profits elsewhere.

The Way Forward: Striking a Balance Between Patent Protection and Public Health

The debate surrounding Section 3(d) of India's Patent Law highlights the ongoing struggle to balance intellectual property (IP) rights and public health needs. While the provision has been instrumental in ensuring affordable access to medicines, it has also been criticized for discouraging pharmaceutical innovation. Moving forward, India and other nations can adopt a balanced approach that fosters both innovation and accessibility.

1. Strengthening the Existing Patent Framework

a) Clearer Guidelines for Patent Examiners

- To avoid ambiguity and inconsistent application of Section 3(d), India can develop comprehensive guidelines for patent examiners.
- A structured framework could help differentiate between genuine innovations and attempts at evergreening, ensuring fair and transparent decision-making.

b) Fast-Track Patents for Genuine Innovations

- While restricting evergreening, India can introduce a fast-track mechanism for patents on truly innovative and life-saving drugs (e.g., new chemical entities or breakthrough treatments).
- This would incentivize R&D investment without compromising affordability.

2. Encouraging Pharmaceutical Innovation in India

a) Public-Private Partnerships (PPPs) for Drug Research

- The government can collaborate with pharmaceutical companies, universities, and research institutes to develop new drugs.
- These partnerships can provide funding, infrastructure, and expertise while ensuring that drug prices remain affordable.

b) Incentives for Domestic Pharmaceutical Companies

- India can offer tax breaks, grants, and subsidies to domestic firms that invest in original drug research, encouraging them to focus on innovation rather than generics alone.
- Special R&D zones or funding initiatives for biotech and pharmaceutical startups could drive homegrown innovation.

3. Ensuring Affordable Access to Medicines

a) Expanding Compulsory Licensing Where Necessary

- While compulsory licensing has been a controversial issue, it remains an important tool for ensuring affordability in cases of public health emergencies (e.g., pandemics, rare diseases).
- India can create a transparent, case-by-case process to determine when compulsory licenses should be granted, avoiding blanket opposition to patents.

b) Tiered Pricing Models

- Pharmaceutical companies can adopt a tiered pricing strategy, where the same drug is sold at different prices in different markets based on economic conditions.
- This would allow companies to maintain profits in high-income countries while ensuring affordable access in low- and middle-income nations.

c) Strengthening Generic Drug Manufacturing

- India must continue supporting its generic drug industry, ensuring that life-saving medicines remain affordable for domestic and global populations.
- Regulatory reforms should streamline the approval process for generics while maintaining quality standards.

4. Addressing Global IP Pressures While Retaining Sovereignty

a) Engaging in International Negotiations on Patent Flexibilities

- India should continue advocating for TRIPS flexibilities, ensuring that WTO regulations do not undermine national public health policies.
- Active participation in international forums (e.g., WTO, WHO, WIPO) can help India push for balanced IP frameworks that consider both innovation and accessibility.

b) Strengthening Regional Cooperation

- India can collaborate with other developing nations to negotiate fairer IP terms in trade agreements.
- Platforms like BRICS, ASEAN, and SAARC can be used to promote collective strategies for managing patent laws while ensuring affordable healthcare.[17]

[17] Indian Ministry of Commerce and Industry, 'Report on the Impact of Section 3(d) on Pharmaceutical Innovation' (2020) https://dipp.gov.in accessed 02 March 2025.

Conclusion

The intersection of patent protection and public health is a complex yet crucial issue, especially in developing countries like India. Section 3(d) of the Indian Patent Act has played a pivotal role in ensuring affordable access to medicines by preventing pharmaceutical companies from obtaining patents for minor modifications of existing drugs. This provision has strengthened India's generic drug industry, making life-saving medicines available at lower costs, both domestically and globally.

However, Section 3(d) has also been met with criticism from multinational pharmaceutical firms and international trade bodies, who argue that it discourages innovation and deters investment in new drug development. While India has successfully defended its stance in landmark cases such as Novartis v. Union of India, it continues to face global pressure to amend its patent laws in favor of stronger IP protection.

Moving forward, a balanced approach is essential—one that incentivizes genuine pharmaceutical innovation while ensuring that critical medicines remain affordable. This can be achieved through clearer patent examination guidelines, stronger public-private partnerships in drug research, expanded compulsory licensing in exceptional cases, and international cooperation on IP flexibilities.

India's patent framework should evolve to foster innovation without compromising accessibility, maintaining its position as the "pharmacy of the developing world" while also becoming a hub for cutting-edge pharmaceutical research. By striking this balance, India can create a sustainable and equitable patent system that serves both public health interests and economic growth.[18]

References

Books:

- Basheer, Shamnad, Patent Law in India: A Critical Analysis of Section 3(d) (Oxford University Press, New Delhi, 2018).

[18] Sudip Chaudhuri, 'TRIPS and Changes in Pharmaceutical Patent Regime in India' (2005) 40(1) *Economic & Political Weekly* 69.

- Correa, Carlos M., Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (Zed Books, London, 2000).
- Dhar, Biswajit & Gopakumar, K.M., Access to Medicines in the Globalised Economy: Intellectual Property Rights and Public Health (Routledge India, New Delhi, 2019).

Articles:

- Basheer, Shamnad, 'India's Tryst with TRIPS: The Novartis Case and Section 3(d)' (2013) 45(2) Journal of Indian Law and Society 67.
- Gopakumar, K.M., 'Product Patents and Access to Medicines in India: A Critical Review of Novartis v. Union of India' (2014) 56(3) Economic & Political Weekly 45.
- Chaudhuri, Sudip, 'TRIPS and Changes in Pharmaceutical Patent Regime in India' (2005) 40(1) Economic & Political Weekly 69.

Cases:

- Novartis AG v. Union of India, (2013) 6 SCC 1.
- Bayer Corporation v. Union of India, (2014) 7 SCC 56.
- F. Hoffmann-La Roche Ltd. v. Cipla Ltd., (2009) 40 PTC 125 (Del).

Statutes and International Treaties:

- The Patents Act, 1970 (as amended in 2005).
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), 1994.
- Doha Declaration on the TRIPS Agreement and Public Health, 2001.

Reports and Government Documents:

- Indian Ministry of Commerce and Industry, 'Report on the Impact of Section 3(d) on Pharmaceutical Innovation' (2020) https://dipp.gov.in accessed 02 March 2025.
- World Health Organization (WHO), 'Access to Essential Medicines: A Global Perspective' (2018) https://who.int/publications accessed 02 March 2025.
- WTO, 'Panel Report on TRIPS Flexibilities and Public Health' (2019) https://wto.org accessed 02 March 2025.

Online Sources:

- Medecins Sans Frontieres (MSF), 'Pharmaceutical Patents and Access to Medicines: India's Role in the Global Health Crisis' (2021) https://msf.org accessed 02 March 2025.
- Indian Patent Office, 'Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals' (2022) https://ipindia.gov.in accessed 02 March 2025.